Long noncoding RNA SNHG14 promotes malignancy of prostate cancer by regulating with miR-5590-3p/YY1 axis

被引:4
|
作者
Luo, Z-F [1 ,2 ]
Peng, Y. [1 ,2 ]
Liu, F-H [1 ,2 ]
Ma, J-S [1 ,2 ]
Hu, G. [1 ,2 ]
Lai, S-L [1 ,2 ]
Lin, H. [1 ,2 ]
Chen, J-J [1 ,2 ]
Zou, G-M [1 ,2 ]
Yan, Q. [1 ,2 ]
Sui, W-G [1 ,2 ]
机构
[1] Southern Med Univ, Sch Clin Med 1, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Affiliated 924 Mil Hosp, Guangxi Key Lab Metab Dis Res, Dept Nephrol,181 Mil Hosp, Guilin, Guangxi, Peoples R China
关键词
Lnc-SNHG14; MiR-5590-3p; YY1; Cell invasion; Apoptosis; Prostate cancer; STATISTICS; PROGRESSION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Studies have demonstrated that long non-coding RNAs (lncRNAs) are important in the development and prognosis of prostate cancer. The aim of this study was to investigate the functions and mechanism of lnc-SNHG14 in prostate cancer. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) or Western blot (WB) were performed to detect mRNA expressions of SNHG14 and miR-5590-3p, and the protein levels of Yin Yang-1 (YY1) in prostate cancer tissues, adjacent tissues, and cancer cell lines. The correlation analysis was used to analyze the correlations between SNHG14, miR-55903p, and YY1. Kaplan-Meier survival analysis was used to analyze the overall survival for prostate cancer patients. Cell Counting Kit-8 (CCK-8) assay was performed to measure cell proliferation ability and flow cytometry assay was used to detect cell apoptotic rate. Besides, transwell assay was used to measure cell invasion ability. In addition, WB was performed to measure protein expressions in prostate cancer cell lines. Finally, Luciferase reporter assay was performed to verify the binding sites between SNHG14 and miR-5590-3p, miR-5590-3p, and YY1. RESULTS: The results showed that SNHG14 was significantly increased in prostate cancer tissues and prostate cancer cell lines, which were related with advanced stage and poor diagnosis for prostate cancer patients. MiR-5590-3p was reduced in prostate cancer tissues and cell lines, which were negatively correlated with SNHG14. YY1 was found to be increased in prostate cancer tissues, which was negatively correlated with miR-5590-3p and positively correlated with SNHG14. Furthermore, SNHG14 knockdown inhibited cell proliferation, invasion, and promoted cell apoptosis in DU145 cells. In addition, protein expressions of Cyclin D1, Bcl-2, and N-cadherin were repressed, and the levels of Bax, Cleaved Caspase-3, and E-cadherin were increased. Besides, miR-5590-3p inhibition promoted cell proliferation and invasion, and inhibited apoptosis in DU145 cells. Importantly, Luciferase reporter assay proved that SNHG14 could directly sponge with miR-5590-3p, which could bind with YY1 and regulate the functions of cancer cell. Finally, we proved that SNHG14 regulated cell proliferation, cell apoptosis, and invasion via miR-5590-3p/YY1 axis in prostate cancer. CONCLUSIONS: Above all, we found that SNHG14 was increased in prostate cancer patients, which was related with future diagnosis for prostate cancer patients. Of note, we discovered that SNHG14 could promote cell proliferation, invasion, and repress cell apoptosis via miR-55903p/YY1 axis in prostate cancer, which might provide a new target for treating prostate cancer.
引用
收藏
页码:4697 / 4709
页数:13
相关论文
共 50 条
  • [1] Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis
    Liao, Zhibin
    Zhang, Hongwei
    Su, Chen
    Liu, Furong
    Liu, Yachong
    Song, Jia
    Zhu, He
    Fan, Yawei
    Zhang, Xuewu
    Dong, Wei
    Chen, Xiaoping
    Liang, Huifang
    Zhang, Bixiang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [2] Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis
    Zhibin Liao
    Hongwei Zhang
    Chen Su
    Furong Liu
    Yachong Liu
    Jia Song
    He Zhu
    Yawei Fan
    Xuewu Zhang
    Wei Dong
    Xiaoping Chen
    Huifang Liang
    Bixiang Zhang
    Journal of Experimental & Clinical Cancer Research, 40
  • [3] Long noncoding RNA SNHG14 promotes osteosarcoma progression via miR-433-3p/FBXO22 axis
    Hou, Xun-Kai
    Mao, Jun-Sheng
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 523 (03) : 766 - 772
  • [4] Long Noncoding RNA SNHG14 Promotes Ischemic Brain Injury via Regulating miR-199b/AQP4 Axis
    Guanglin Zhang
    Tianxiao Li
    Xiaozan Chang
    Jun Xing
    Neurochemical Research, 2021, 46 : 1280 - 1290
  • [5] Long Noncoding RNA SNHG14 Promotes Ischemic Brain Injury via Regulating miR-199b/AQP4 Axis
    Zhang, Guanglin
    Li, Tianxiao
    Chang, Xiaozan
    Xing, Jun
    NEUROCHEMICAL RESEARCH, 2021, 46 (05) : 1280 - 1290
  • [6] RETRACTED: Long noncoding RNA SNHG14 promotes breast cancer cell proliferation and invasion via sponging miR-193a-3p (Retracted Article)
    Xie, S-D
    Qin, C.
    Jin, L-D
    Wang, Q-C
    Shen, J.
    Zhou, J-C
    Chen, Y. X.
    Huang, A-H
    Zhao, W-H
    Wang, L-B
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (06) : 2461 - 2468
  • [7] Long noncoding RNA SNHG1 promotes breast cancer progression by regulating the miR-641/RRS1 axis
    Deng, Lin
    Wang, Jun
    Song, Junying
    Wu, Qinglan
    Gong, Zunshuang
    Song, Jinlian
    Hou, Lin
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [8] Long noncoding RNA SNHG14 facilitates hepatocellular carcinoma progression through regulating miR-4673/SOCS1
    Pu, Jian
    Wei, Huamei
    Tan, Chuan
    Qin, Bangze
    Zhang, Ya
    Wang, Anmin
    Wang, Jianchu
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (09): : 5897 - 5904
  • [9] Long noncoding RNA SNHG1 promotes breast cancer progression by regulating the miR-641/RRS1 axis
    Lin Deng
    Jun Wang
    Junying Song
    Qinglan Wu
    Zunshuang Gong
    Jinlian Song
    Lin Hou
    Scientific Reports, 14
  • [10] Long Noncoding RNA SNHG1 Contributes to the Promotion of Prostate Cancer Cells Through Regulating miR-377-3p/AKT2 Axis
    Xie, Mao
    Zhang, Zhiyu
    Cui, Yupeng
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (02) : 109 - 119